Trendlines says its most valuable portfolio company is Stimatix
Stimatix sold its assets in Nov 2014 to a B Braun subsidiary; Trendlines' current holding of 28.2% valued at US$42.6m
Add BT as a preferred sourceSingapore
CATALIST-LISTED The Trendlines Group - an Israel and Singapore-based incubator of medtech and agritech startups - has disclosed that an asset it described as its "Most Valuable Portfolio Company" is Stimatix GI.
In a statement on Monday, Trendlines said that Stimatix, which develops medical products to aid patients with intestinal blockage, sold its assets in November 2014 to a subsidiary of German medical device company B Braun Group. B Braun will market Stimatix's ostomy products internationally from mid-2018.
TRENDING NOW
Qatari LNG ship struck in Strait of Hormuz, testing US talks
DBS, OCBC and UOB shares hit all-time highs as sentiment improves
‘Baptism of fire’: Andre Khor on leading Singapore refiner Aster through an energy crisis
Singapore retains top spot as most expensive city for HNWIs, with five Apac cities in global top 10
